Posted in | News | Mining Business

DIAGNOS Earns Additional Interests on Majescor Resources

Diagnos Inc., a leader in early detection of critical health issues through the use of Artificial Intelligence, announces that, as stated in a news release dated May 17th, 2017 by Majescor Resources Inc., Majescor has received regulatory and shareholders' approval for the issuance to the Corporation of 8,000,000 common shares pursuant to the sale of the assets from its mining division announced on March 15th, 2017.

The news release from Majescor triggered the requirement to file an early warning report ("Form 62-103F1") by DIAGNOS and to publish this press release.

DIAGNOS currently owns 2,500,000 Shares of the Issuer representing an approximate 6.18% of the outstanding Shares of the Issuer on an undiluted basis and partially diluted basis. Immediately following the issuance of 8,000,000 Shares, DIAGNOS will own, directly and indirectly, 10,500,000 Shares, representing an approximate 21.68% interest in the Issuer on an undiluted basis and partially diluted basis.

DIAGNOS' investment in Shares of Majescor is solely for investment purposes. Based upon subsequent developments affecting the Issuer or its business and the general market and economic conditions, DIAGNOS may decide to purchase additional securities of the Issuer or may decide to sell all or part of its investments.

A copy of Form 62-103F1 can be found on SEDAR.com or may be obtained by submitting a written request to:

Diagnos Inc.
c/o Accounting and Legal Dept.
7005 Taschereau Blvd, suite 340
Brossard, Qc, J4Z 1A7
450-678-8882 ext. 235

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.